Cancer Type: Brain tumor, adult: General and other
Stage/Subtype of Cancer: medulloblastoma, adult
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Other
Protocol IDs: CNS 0201, NCT00179907
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BC-BT-9, NCT00003457
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BC-BT-21, NCT00003475
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: NCI
Protocol IDs: MSKCC-02088, NCT00058370
|
|
6.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GLIA-001, NCT00525590
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 3368, NCT00576537
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 12555, NCT00589706
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 00003596, NCT00611325
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 00000379, NCT00612430
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months and over
Sponsor: NCI
Protocol IDs: OHSU-1299, OHSU-ONC-98018-L, OHSU-4834, NCT00253721
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: NCI
Protocol IDs: CPMC-AAAA-4229, CPMC-14220, NCT00324844
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 05C.255, NCT00329589
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06C.549, NCT00437372
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: 2004-0079, NCT00502892
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 2007-0370, NCT00513162
|
|
20.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-04032, 04032, NCT00544284
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: UMN-2005LS023, UMN-2005LS023, UMN-MT2004-30, NCT00623077
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07C.381, NCT00639262
|
|
23.
|
Phase: Phase I
Type: Diagnostic, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 4079, NCT00671710
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-07064, 07064, NCT00784914
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: TPI-287, NCT00867568
|
